Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Aminophylline for treatment of postdural puncture headache
Neurol 90:e1523-e1529, Wu, C.,et al, 2018
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
A Randomized Trial of Telemedicine Efficacy and Safety for Nonacute Headaches
Neurol 89:153-162, Muller, K.I.,et al, 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache
Neurol 86:1818-1826, Simpson, D.M.,et al, 2016
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults
Neurol 78:1346-1353, Holland,S.,et al, 2012
Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults
JAMA 307:1736-1745, Jackson,J.L.,et al, 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
OnabotulinumtoxinA Improves Quality of Life and Reduces Impact of Chronic Migraine
Neurol 77:1465-1472, Lipton, R.B.,et al, 2011
Intravenous Dihydroergotamine for Inpatient Management of Refractory Primary Headaches
Neurol 77:1827-1832, Nagy, A.J.,et al, 2011
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Tricyclic Antidepressants and Headaches: Systematic Review and Meta-Analysis
BMJ 341:c5222, Jackson,J.L.,et al, 2010
Oxcarbazepine in Migraine Headache: A Double-Blind, Randomized, Placebo-Controlled Study
Neurol 70:548-555, Silberstein,S.,et al, 2008
Treatment of Medically Intractable Cluster Headache by Occipital Nerve Stimulation: Long-Term Follow-Up of Eight Patients
Lancet 369:1099-1065, Burns,B.,et al, 2007
Sumatriptan-Naproxen for Acute Treatment of Migraine, A Randomized Trial
JAMA 297:1443-1454, Brandes,J.L.,et al, 2007
Neurological Complications With Acute Sphenoid Sinusitis a Surgical Emergency?
Neurocrit Care 7:169-171, Poulopoulos,M. &Finelli,P.F., 2007
Zolmitriptan Nasal Spray in the Acute Treatment of Cluster Headache: A Double-Blind Study
Neurol 69:821-826, Rapoport,A.M.,et al, 2007
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Tenecteplase for Stroke - Opening the Window?
NEJM 390:760-761, Leifer,D.,, 2024
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients with Standard Surgical Risk
JAMA Neurol 80:437-444,435, Liang,P.,et al, 2023
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion
NEJM 388:2025-2095, Zi,W.,et al, 2023
Endovascular Therapy Versus Medical Treatment for Symptomatic Intracranial Artery Stenosis
Stroke 54:e305-e306, Luo,J.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
National Trends of Cerebral Venous Sinus Stenting for the Treatment of Idiopathic Intracranial Hypertension
Neurol 101:402-406, Khunte,M.,et al, 2023
Lecanemab, Looking Before We Leap
Neurol 101:661-665, Burke,J.F.,et al, 2023
Trial of Botulinum Toxin for Isolated or Essential Head Tremor
NEJM 389:1753-1765, Marques,A.,et al, 2023
Improving Neurology Clinical Care with Natural Language Processing Tools
Neurol 101:1010-1018, Ge,W.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Use of GPT-4 to Diagnose Complex Clinical Cases
NEJM AI doi:10.1056/AIp2300031, Eriksen,A.V.,et al, 2023
Study Finds ChatGPT Provides Inaccurate Responses to Drug Questions-Press Release
Am Soc Health Sys Pharm, Dec 5, Grossman,S., 2023
Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation
Ann Neurol 91:78-88, Polymeris, A.A.,et al, 2022
Lentiviral Haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access
Lancet 399:372-383, Fumagalli, F.,et al, 2022
Efficacy and Safety of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1
Neurol 98:e938-e946, Hwang, J.,et al, 2022